Composite bioactive peptide composition for improving joint injury and preparation method thereof

Abstract

The invention relates to the technical field of health food, in particular to a composite bioactive peptide composition for improving joint injury and a preparation method thereof, and the composition comprises the following raw materials: yak bone oligopeptide, yak bone marrow, whole milk, bovine brain peptide, hyaluronic acid, tea polyphenol and a sweetening agent.

Description

Technical Field

[0001] This invention belongs to the field of health food technology, specifically relating to a compound bioactive peptide composition for improving joint damage and its preparation method. Background Technology

[0002] With the development of the health industry, bioactive peptides derived from natural products have attracted much attention due to their outstanding functional properties. Among them, yak bone marrow peptides, with their unique amino acid sequence and rich nutritional composition, have been shown by studies to have significant potential in alleviating joint wear and tear, repairing cartilage tissue, and improving osteoarthritis symptoms, making them a highly promising functional raw material for joint health.

[0003] Currently, most products on the market for osteoarthritis use a single main ingredient to treat osteoarthritis, such as glucosamine for osteoarthritis repair. This method of relying on a single ingredient for treatment is not very effective. Summary of the Invention

[0004] (1) Technical problems to be solved The purpose of this invention is to provide a compound bioactive peptide composition for improving joint damage and its preparation method, in order to solve the problem that products on the market for osteoarthritis generally use a single main ingredient to regulate osteoarthritis, such as using glucosamine to achieve osteoarthritis repair. This method of relying mainly on a single ingredient for regulation has an unsatisfactory conditioning effect.

[0005] (2) Technical solution To achieve the above objectives, on the one hand, the present invention provides a composite bioactive peptide composition for improving joint damage, the raw materials of which include: yak bone oligopeptides, yak bone marrow, whole milk, bovine brain peptides, hyaluronic acid, tea polyphenols and sweeteners.

[0006] Furthermore, the raw materials of the composition further include: phosphatidylserine, nervonic acid, modified chitosan, food-grade silica, and modified corn starch.

[0007] Further, the composition comprises: 3-10 parts of yak bone oligopeptide, 10-20 parts of yak bone marrow, 50-70 parts of whole milk, 0.5-1.5 parts of bovine brain peptide, 0.5-1 part of hyaluronic acid, 0.1-0.5 parts of tea polyphenols, and 10-20 parts of sweetener.

[0008] Further, the composition comprises: 0.3-1 parts of phosphatidylserine, 0.2-0.5 parts of nervonic acid, 3-8 parts of modified chitosan, 0.05-0.1 parts of food-grade silica, and 20-40 parts of modified corn starch.

[0009] Furthermore, the modified chitosan is grafted with succinyl and hydroxypropyl groups.

[0010] Furthermore, the modified corn starch incorporates phosphate crosslinking groups and octenyl succinic acid groups.

[0011] Furthermore, the food-grade silica is bioactive silica, which is silicate and / or organosilicon.

[0012] Furthermore, the composition is used to improve osteoarticular injuries and is applicable to the acute, recovery, and maintenance phases of osteoarticular injuries.

[0013] Furthermore, the dosage form of the composition is oral.

[0014] The present invention also provides a method for preparing a complex bioactive peptide composition for improving joint damage. This method is used to prepare the composition described in this claim, and the method includes: S1: Pretreatment steps include active peptide dissolution, lipid-soluble component emulsification, modified chitosan hydration, and silica dispersion; wherein, the active peptide dissolution is achieved by mixing the yak bone oligopeptides and the bovine brain peptides, adding 50% of the formulated amount of pure water, stirring the solution, and obtaining a peptide aqueous mother liquor; the lipid-soluble component emulsification is achieved by mixing the phosphatidylserine, the nervonic acid, and the yak bone marrow, adding the modified corn starch, dissolving it in polyethylene glycol, and then emulsifying it under high-speed shearing to obtain a lipid-soluble mother liquor; the modified chitosan hydration is achieved by adding the modified chitosan to 10% of the formulated amount of pure water, stirring in a 50°C water bath until completely dissolved, and obtaining a chitosan aqueous phase liquid; the silica dispersion is achieved by adding the food-grade silica to 5% of the formulated amount of pure water, ultrasonically dispersing it, and obtaining a silica dispersion. S2: Mixed emulsification step, adding the chitosan aqueous solution and the lipid-soluble mother liquor to the peptide aqueous phase mother liquor, stirring evenly, then adding the silica dispersion and the hyaluronic acid, stirring evenly to obtain a mixed emulsion; S3: High-pressure homogenization step, the mixed emulsion is transferred to a high-pressure homogenizer and homogenized twice; S4: Antioxidant step, add the tea polyphenols and the sweetener, stir to dissolve, adjust the pH to 6.0-6.5, and add pure water to the preset volume; S5: Filtration and clarification step, removing impurities and large particles through microporous membrane filtration; S6: Low-temperature sterilization, using pasteurization method, 60℃ for 30 minutes; S7: Aseptic filling stage. After low-temperature sterilization, the temperature is lowered to room temperature and aseptic filling is performed to obtain a complex bioactive peptide composition solution.

[0015] The composite bioactive peptide composition for improving joint damage provided in the embodiments of this specification comprises the following raw materials: yak bone oligopeptides, yak bone marrow, whole milk, bovine brain peptides, hyaluronic acid, tea polyphenols, and sweeteners. The yak bone oligopeptides, yak bone marrow, bovine brain peptides, hyaluronic acid, and tea polyphenols enable multiple substances to achieve the purpose of improving joint damage, exhibiting a synergistic effect. Furthermore, modified corn starch is added to the composition. The phosphate ester crosslinking groups and octenyl succinic acid groups introduced into the modified corn starch, along with modified chitosan, achieve a synergistic effect, thereby enhancing the effect of improving joint damage. Attached Figure Description

[0016] Figure 1 This is a flowchart illustrating the preparation of a composite bioactive peptide composition for improving joint damage, as described in Example 1 of the present invention. Detailed Implementation

[0017] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0018] This specification provides an example of a complex bioactive peptide for improving joint damage. The raw materials of this composition include: yak bone oligopeptides, yak bone marrow, whole milk, bovine brain peptides, hyaluronic acid, tea polyphenols, and sweeteners.

[0019] In the embodiments of this specification, the yak bone oligopeptides have a molecular weight of less than 1000 Da and are small molecule oligopeptides extracted from yak bones. The extraction method for yak bone oligopeptides employs biotechnology, such as enzymatic hydrolysis followed by low-temperature purification, or other methods. The method of obtaining yak bone oligopeptides does not constitute a limitation of this application and will not be elaborated further here. In this embodiment, the yak bone oligopeptides maintain their activity in the composite bioactive peptide composition, thereby ensuring their effectiveness. The molecular weight of the yak bone oligopeptides is preferably less than 500 Da, and the yak bone oligopeptides are added to the composite bioactive peptide composition in the form of lyophilized powder. In the embodiments of this specification, yak bone oligopeptides serve as the main active peptide for joint repair, activating chondrocyte proliferation, promoting the synthesis of type II collagen and proteoglycans, and enhancing cartilage toughness.

[0020] Yak bone marrow serves as a nutrient matrix carrier, providing nutrients such as calcium, phosphorus, and collagen to promote joint repair. In this embodiment, yak bone marrow is added to the composite bioactive peptide composition in the form of low-temperature freeze-dried powder. This allows the yak bone marrow to retain its proteins, active factors, and other nutrients while removing excess fat and impurities, meeting food-grade production standards and enabling direct use in the preparation of the composite bioactive peptide composition. The preparation method of yak bone marrow does not constitute a limitation of this application and will not be elaborated further here.

[0021] Whole milk serves as a protein carrier and stabilizer, providing whey protein, casein, and lactose to maintain the fluidity and absorption environment of the complex bioactive peptide composition system. In this embodiment, the whole milk needs to be defatted to ensure that the oral liquid does not become cloudy due to excessive fat content in the whole milk.

[0022] Bovine brain peptides are active small molecule peptides extracted from bovine brain. As the core active ingredient, bovine brain peptides primarily function for nerve repair. The extraction method for bovine brain peptides utilizes existing technology and is not intended to limit this application; therefore, it will not be elaborated further. In this embodiment, bovine brain peptides are added to the composite bioactive peptide composition in the form of lyophilized powder. The form in which the lyophilized bovine brain peptide powder is obtained is not intended to limit this application and will not be elaborated further.

[0023] Hyaluronic acid polymer chains can form a network structure in water, thereby increasing the viscosity of the oral liquid and having a thickening effect; it also improves the taste of the oral liquid. Furthermore, as a natural component of synovial fluid, hyaluronic acid can synergistically work with yak bone oligopeptides. By activating CD44 receptors on the surface of chondrocytes, it upregulates the synthesis of type II collagen and proteoglycans, accelerating the repair of damaged cartilage matrix. Simultaneously, it can inhibit the release of inflammatory factors within the joint cavity, reducing joint swelling and pain, and has anti-inflammatory and swelling-reducing effects. In this embodiment, hyaluronic acid is added to the composite bioactive peptide composition in the form of food-grade solid powder. The method of obtaining hyaluronic acid does not constitute a limitation of this application and will not be elaborated here.

[0024] Tea polyphenols, as antioxidants, can inhibit the Maillard reaction of proteins in yak bone marrow and whole milk, preventing problems such as darkening of color and the development of off-flavors during the storage period of oral liquids. Simultaneously, as an anti-inflammatory factor, tea polyphenols can reduce the release of pro-inflammatory factors, such as interleukin-6 and tumor necrosis factor-α, thereby alleviating joint swelling and pain and assisting active peptides in repairing cartilage tissue. In this embodiment, tea polyphenols are added to the composite bioactive peptide composition in the form of food-grade solid powder. The method of obtaining tea polyphenols does not constitute a limitation of this application and will not be elaborated here.

[0025] In the embodiments of this specification, the composition comprises: 3-10 parts of yak bone oligopeptide, 10-20 parts of yak bone marrow, 50-70 parts of whole milk, 0.5-1.5 parts of bovine brain peptide, 0.5-1 part of hyaluronic acid, 0.1-0.5 parts of tea polyphenols, and 10-20 parts of sweetener.

[0026] To further improve the effect of joint injury, the raw materials of the composition further include: phosphatidylserine, nervonic acid, modified chitosan, food-grade silica and modified corn starch.

[0027] In the embodiments of this specification, phosphatidylserine, as a key component of the cell membrane, can participate in maintaining the fluidity of the cell membrane. It can work synergistically with bovine brain peptides and nervonic acid, and achieve nutritional complementarity with yak bone oligopeptides and yak bone marrow. At the same time, it promotes the transmembrane absorption of yak bone oligopeptides and bovine brain peptides, reduces the degradation of the composition in vivo, and prolongs the efficacy.

[0028] Nervonic acid, or 24-carbon-cis-15-enoic acid, is an unsaturated long-chain fatty acid containing 24 carbon atoms and one double bond. It is mainly found in nerve tissue and some vegetable oils. In the embodiments of this specification, nervonic acid is added in food-grade powder form. The method of obtaining nervonic acid adopts existing technology and will not be described in detail here.

[0029] Nervonic acid synergistically enhances the effects of bovine brain peptides and phosphatidylserine. As a key component of brain nerve cell membranes and myelin sheaths, nervonic acid compensates for the body's insufficient synthesis capacity. Together with bovine brain peptides, it supplements nerve nutrition, strengthening the neurotrophic value of the oral liquid. It also forms a comprehensive nutritional complement with yak bone oligopeptides for bone nutrition and hyaluronic acid for joint nutrition. Simultaneously, nervonic acid and phosphatidylserine work together to participate in the construction and repair of the cell membrane phospholipid bilayer, jointly maintaining the integrity and fluidity of the cell membrane. This promotes the absorption and action of bovine brain peptides and yak bone oligopeptides at the cellular level, reduces the degradation of peptide components in the body, and prolongs the duration of efficacy, thereby achieving the goal of synergistically enhancing the active components of peptides. In the embodiments of this specification, the composition comprises: 0.3-1 parts of phosphatidylserine, 0.2-0.5 parts of nervonic acid, 3-8 parts of modified chitosan, 0.05-0.1 parts of food-grade silica, and 20-40 parts of modified corn starch.

[0030] In the embodiments described in this specification, the modified chitosan is grafted with succinyl and hydroxypropyl groups.

[0031] Modified chitosan uses food-grade chitosan as the matrix material and introduces succinyl and hydroxypropyl groups into the amino and hydroxyl sites of the chitosan molecular chain through a chemical grafting reaction to form bisubstituted modified chitosan. This retains the biocompatibility of chitosan while increasing the functionality of the bifunctional groups.

[0032] In one embodiment of this specification, the method for preparing modified chitosan includes the following steps: Step S101: Chitosan activation and swelling. Specifically, purified water is added to chitosan, the pH is adjusted to 5.0-5.5 with citric acid, and the mixture is stirred at room temperature for 1 hour to form a uniform suspension. Step S103: Hydroxypropyl modification. Specifically, the homogeneous suspension obtained in step S101 is heated to 50-55℃, propylene oxide is slowly added, and the mixture is stirred at a constant temperature for 4-6 hours. After the reaction is completed, it is cooled to room temperature to obtain a hydroxypropyl chitosan intermediate, wherein the molar ratio of chitosan to propylene oxide is 1:3 to 1:5. Through hydroxypropyl modification, the first step of modification of chitosan is achieved, which significantly improves water solubility, reduces intermolecular hydrogen bonds, and improves compatibility.

[0033] Step S105: Succinyl grafting. Specifically, the system temperature of the hydroxypropyl chitosan intermediate obtained in step S103 is maintained at 40-45℃, the pH is finely adjusted to 6.0-6.5 with NaOH, succinic anhydride is added, and the reaction is carried out at a constant temperature for 3-4 hours to complete the succinyl grafting. The molar ratio of chitosan to succinic anhydride is 1:2 to 1:3. The second step of modification of chitosan is achieved through succinyl grafting. Introducing carboxyl groups in this process can enhance water solubility and complexing properties, and maintain the stability of the system. Step S107: Dialysis purification. Specifically, the reaction solution obtained in step S105 is placed into a dialysis bag with a molecular weight cutoff of 8000-10000 Da and dialyzed with purified water for 48 hours, with the water changed every 6 hours, to remove unreacted small molecules, salts and residual reagents. Step S109: Concentration and freeze-drying. Specifically, the dialysate from step S107 is concentrated under reduced pressure at 45°C to a solid content of 2%-3%, and then freeze-dried under vacuum to obtain modified chitosan for use in the preparation of a composite bioactive peptide composition. In this embodiment, the vacuum freeze-drying process involves pre-freezing at -40°C for 3 hours, sublimation drying for 8 hours, and desorption drying for 4 hours.

[0034] In the embodiments described in this specification, the modified corn starch is incorporating phosphate crosslinking groups and octenyl succinic acid groups.

[0035] In the embodiments of this specification, the preparation method of modified corn starch includes the following steps: S201. Add waxy corn starch and deionized water to the reaction vessel, stir to form starch slurry, adjust the pH to 10.5, dissolve sodium tripolyphosphate in deionized water, add it dropwise to the starch slurry, stir to react, after the reaction is completed, adjust the pH to 6.5 to obtain cross-linked starch slurry; S203. Adjust the pH of the above cross-linked starch milk to 8.5, add octenyl succinic anhydride dropwise to the liquid surface, stir the reaction, after the reaction is complete, adjust the pH to 6.5, centrifuge, resuspend the precipitate with deionized water and centrifuge again, vacuum dry the obtained wet starch cake, crush the dried block and sieve to obtain modified corn starch.

[0036] Sodium trimetaphosphate, as a specialized reagent for phosphate ester cross-linking reactions, undergoes a cross-linking reaction with corn starch molecular chains during the preparation of modified corn starch, forming a stable phosphate ester cross-linking structure. This significantly improves the temperature resistance, acid resistance, and shear resistance of the modified starch, making it suitable for oral liquids. It also prevents system turbidity and precipitation caused by the degradation of modified starch, ensuring the long-term storage stability of the oral liquid.

[0037] In the embodiments of this specification, the food-grade silica is bioactive silica, which is silicate and / or organosilicon.

[0038] The silicate can be metasilicate, orthosilicate, or pyrosilicate, with metasilicate being preferred. The metasilicate is sodium metasilicate or potassium metasilicate.

[0039] Organosilicon can be an organosilane, silanol, organosilicon ester, or organosilicon derivative, preferably an organosilane. The organosilane is tri-aminopropyltriethoxysilane, the silanol is polyethylene glycol silanol, the organosilicon ester is methyl silicate or ethyl silicate, and the organosilicon derivative is a silane derivative.

[0040] Food-grade silica in this composition can stabilize the system, while also optimizing the taste and aiding solubility, ultimately improving the nutritional value and storage stability of the composition.

[0041] In the embodiments of this specification, the composition is used to improve bone and joint injuries and is applicable to the acute, recovery, and maintenance phases of bone and joint injuries.

[0042] The composition of this application is suitable for use in the acute, recovery and maintenance phases of bone and joint injuries, and achieves different effects depending on the dosage used orally.

[0043] In the embodiments described in this specification, the dosage form of the composition is oral.

[0044] Example 1: This example discloses a composite bioactive peptide composition for improving joint damage, comprising the following parts by weight: 3 parts yak bone oligopeptide, 10 parts yak bone marrow, 50 parts whole milk, 0.5 parts bovine brain peptide, 0.5 parts hyaluronic acid, 0.1 parts tea polyphenols, and 10 parts sweetener.

[0045] Example 2: This example is based on Example 1, but differs from Example 1 in that it includes the following weight proportions: 6.5 parts yak bone oligopeptide, 15 parts yak bone marrow, 60 parts whole milk, 1.0 part bovine brain peptide, 0.75 parts hyaluronic acid, 0.3 parts tea polyphenols, and 15 parts sweetener.

[0046] Example 3: This example is based on Example 1, but differs from Example 1 in that it includes the following weight proportions: 10 parts yak bone oligopeptide, 20 parts yak bone marrow, 70 parts whole milk, 1.5 parts bovine brain peptide, 1 part hyaluronic acid, 0.5 parts tea polyphenols, and 120 parts sweetener.

[0047] Example 4: This example is based on Example 1, but differs from Example 1 in that it includes the following components by weight: 3 parts yak bone oligopeptide, 10 parts yak bone marrow, 50 parts whole milk, 0.5 parts bovine brain peptide, 0.5 parts hyaluronic acid, 0.1 parts tea polyphenols, 10 parts sweetener, 0.3 parts phosphatidylserine, 0.2 parts nervonic acid, 3 parts modified chitosan, 0.05 parts food-grade silica, and 20 parts modified corn starch.

[0048] Example 5: 6.5 parts yak bone oligopeptide, 15 parts yak bone marrow, 60 parts whole milk, 1.0 part bovine brain peptide, 0.75 parts hyaluronic acid, 0.3 parts tea polyphenols, 15 parts sweetener, 0.65 parts phosphatidylserine, 0.35 parts nervonic acid, 5.5 parts modified chitosan, 0.75 parts food-grade silica, and 30 parts modified corn starch.

[0049] Example 6: 10 parts yak bone oligopeptides, 20 parts yak bone marrow, 70 parts whole milk, 1.5 parts bovine brain peptides, 1 part hyaluronic acid, 0.5 parts tea polyphenols, 120 parts sweetener, 1 part phosphatidylserine, 0.5 parts nervonic acid, 8 parts modified chitosan, 0.1 parts food-grade silica, and 40 parts modified corn starch. Comparative Example 1: This comparative example is based on Example 4, but differs from Example 4 in that it does not contain phosphatidylserine; Comparative Example 2: This comparative example is based on Example 4, but unlike Example 4, this comparative example does not contain nervonic acid; Comparative Example 3: This comparative example is based on Example 4, but unlike Example 4, this comparative example does not contain modified chitosan; Comparative Example 4: This comparative example is based on Example 4, but differs from Example 4 in that ordinary corn starch is used instead of modified corn starch. Comparative Example 5: This comparative example is based on Example 4, but unlike Example 4, this comparative example does not contain food-grade silica.

[0050] Experiment 1: Verify the performance of the composition in improving joint injury. The results are shown in Table 1.

[0051] 1. Experimental Design: Animal Model: Animals: Male SD rats, 200±20g, 8 weeks old; Model: Knee osteoarthritis model induced by sodium iodoacetate (MIA). Groups: Blank control group (n=10); Model control group (n=10); Positive control group (glucosamine sulfate, n=10); Example 1 group (n=10); Example 2 group (n=10); Example 3 group (n=10); Example 4 group (n=10); Example 5 group (n=10); Example 6 group (n=10); Comparative Example 1 (n=10); Comparative Example 2 (n=10); Comparative Example 3 (n=10); Comparative Example 4 (n=10); Comparative Example 5 (n=10). Drug Administration: Modeling: Intra-articular injection of 3mg MIA (50μL); Drug Administration: Starting 7 days after modeling, daily gavage for 28 consecutive days; Dosage: 500mg / kg / day for all example groups, calculated as yak bone marrow peptide.

[0052] 2. Detection indicators and methods: (1) Behavioral science: Mechanical pain threshold: Von Frey fiber to measure foot mechanical pain; Weight-bearing balance: Bipedal balance tester to measure the weight-bearing ratio of the affected limb.

[0053] (2) Molecular biology: Serum inflammatory factors: IL-1β and TNF-α levels were detected by ELISA; Synovial fluid inflammatory factors: MMP-13 levels were detected by ELISA.

[0054] Table 1. Performance results of the composition in improving joint injury

[0055] As shown in Table 1, both the comparative example and the embodiment can achieve the goal of improving joint damage, and the comparative example is better than the comparative example in improving joint damage.

[0056] Experiment 2: Verify food safety.

[0057] The products prepared according to Examples 1-6 of this application comply with the "National Food Safety Standard for Good Manufacturing Practices for Health Foods" (GB 17405-2025).

[0058] The composite bioactive peptide composition for improving joint damage provided in the embodiments of this specification comprises the following raw materials: yak bone oligopeptides, yak bone marrow, whole milk, bovine brain peptides, hyaluronic acid, tea polyphenols, and sweeteners. The yak bone oligopeptides, yak bone marrow, bovine brain peptides, hyaluronic acid, and tea polyphenols enable multiple substances to achieve the purpose of improving joint damage, exhibiting a synergistic effect. Furthermore, modified corn starch is added to the composition. The phosphate ester crosslinking groups and octenyl succinic acid groups introduced into the modified corn starch, along with modified chitosan, achieve a synergistic effect, thereby enhancing the effect of improving joint damage.

[0059] The present invention also provides a method for preparing a complex bioactive peptide composition for improving joint damage. This method is used to prepare the composition of the present invention, and the method includes: S1: Pretreatment steps include active peptide dissolution, lipid-soluble component emulsification, modified chitosan hydration, and silica dispersion; wherein, the active peptide dissolution is achieved by mixing the yak bone oligopeptides and the bovine brain peptides, adding 50% of the formulated amount of pure water, stirring the solution, and obtaining a peptide aqueous mother liquor; the lipid-soluble component emulsification is achieved by mixing the phosphatidylserine, the nervonic acid, and the yak bone marrow, adding the modified corn starch, dissolving it in polyethylene glycol, and then emulsifying it under high-speed shearing to obtain a lipid-soluble mother liquor; the modified chitosan hydration is achieved by adding the modified chitosan to 10% of the formulated amount of pure water, stirring in a 50°C water bath until completely dissolved, and obtaining a chitosan aqueous phase liquid; the silica dispersion is achieved by adding the food-grade silica to 5% of the formulated amount of pure water, ultrasonically dispersing it, and obtaining a silica dispersion. S2: Mixed emulsification step, adding the chitosan aqueous solution and the lipid-soluble mother liquor to the peptide aqueous phase mother liquor, stirring evenly, then adding the silica dispersion and the hyaluronic acid, stirring evenly to obtain a mixed emulsion; S3: High-pressure homogenization step, the mixed emulsion is transferred to a high-pressure homogenizer and homogenized twice; S4: Antioxidant step, add the tea polyphenols and the sweetener, stir to dissolve, adjust the pH to 6.0-6.5, and add pure water to the preset volume; S5: Filtration and clarification step, removing impurities and large particles through microporous membrane filtration; S6: Low-temperature sterilization, using pasteurization method, 60℃ for 30 minutes; S7: Aseptic filling stage. After low-temperature sterilization, the temperature is lowered to room temperature and aseptic filling is performed to obtain a complex bioactive peptide composition solution.

[0060] The above description is merely a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, and improvements made by those skilled in the art within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A complex bioactive peptide composition for improving joint damage, characterized in that, The raw materials of the composition include: yak bone oligopeptides, yak bone marrow, whole milk, bovine brain peptides, hyaluronic acid, tea polyphenols, and sweeteners.

2. The composite bioactive peptide composition according to claim 1, characterized in that, The raw materials of the composition further include: phosphatidylserine, nervonic acid, modified chitosan, food-grade silica, and modified corn starch.

3. The composite bioactive peptide composition according to claim 1, characterized in that, The composition comprises: 3-10 parts of yak bone oligopeptide, 10-20 parts of yak bone marrow, 50-70 parts of whole milk, 0.5-1.5 parts of bovine brain peptide, 0.5-1 part of hyaluronic acid, 0.1-0.5 parts of tea polyphenols, and 10-20 parts of sweetener.

4. The composite bioactive peptide composition according to claim 2, characterized in that, The composition comprises: 0.3-1 parts of phosphatidylserine, 0.2-0.5 parts of nervonic acid, 3-8 parts of modified chitosan, 0.05-0.1 parts of food-grade silica, and 20-40 parts of modified corn starch.

5. The composite bioactive peptide composition according to claim 2, characterized in that, The modified chitosan is grafted with succinyl and hydroxypropyl groups.

6. The composite bioactive peptide composition according to claim 2, characterized in that, The modified corn starch incorporates phosphate crosslinking groups and octenyl succinic acid groups.

7. The composite bioactive peptide composition according to claim 2, characterized in that, The food-grade silica is bioactive silica, which is silicate and / or organosilicon.

8. The composite bioactive peptide composition according to any one of claims 1-7, characterized in that, The composition is used to improve bone and joint injuries and is applicable to the acute, recovery, and maintenance phases of bone and joint injuries.

9. The complex bioactive peptide composition according to any one of claims 1-7, characterized in that, The composition is in the form of an oral medication.

10. A method for preparing a complex bioactive peptide composition for improving joint damage, characterized in that, The method for preparing the composition is used to prepare the composition according to any one of claims 1-9, wherein the method for preparing the composition comprises: S1: Pretreatment steps include active peptide dissolution, lipid-soluble component emulsification, modified chitosan hydration, and silica dispersion; wherein, the active peptide dissolution is achieved by mixing the yak bone oligopeptides and the bovine brain peptides, adding 50% of the formulated amount of pure water, stirring the solution, and obtaining a peptide aqueous mother liquor; the lipid-soluble component emulsification is achieved by mixing the phosphatidylserine, the nervonic acid, and the yak bone marrow, adding the modified corn starch, dissolving it in polyethylene glycol, and then emulsifying it under high-speed shearing to obtain a lipid-soluble mother liquor; the modified chitosan hydration is achieved by adding the modified chitosan to 10% of the formulated amount of pure water, stirring in a 50°C water bath until completely dissolved, and obtaining a chitosan aqueous phase liquid; the silica dispersion is achieved by adding the food-grade silica to 5% of the formulated amount of pure water, ultrasonically dispersing it, and obtaining a silica dispersion. S2: Mixed emulsification step, adding the chitosan aqueous solution and the lipid-soluble mother liquor to the peptide aqueous phase mother liquor, stirring evenly, then adding the silica dispersion and the hyaluronic acid, stirring evenly to obtain a mixed emulsion; S3: High-pressure homogenization step, the mixed emulsion is transferred to a high-pressure homogenizer and homogenized twice; S4: Antioxidant step, add the tea polyphenols and the sweetener, stir to dissolve, adjust the pH to 6.0-6.5, and add pure water to the preset volume; S5: Filtration and clarification step, removing impurities and large particles through microporous membrane filtration; S6: Low-temperature sterilization, using pasteurization method, 60℃ for 30 minutes; S7: Aseptic filling stage. After low-temperature sterilization, the temperature is lowered to room temperature and aseptic filling is performed to obtain a complex bioactive peptide composition solution.

Images